메뉴 건너뛰기




Volumn 2, Issue 3, 2010, Pages 347-356

Therapeutic antibodies, vaccines and antibodyomes

Author keywords

Antibodies; Antibodyome; Biologicals; Therapeutics; Vaccines

Indexed keywords

CATUMAXOMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; NIMOTUZUMAB; PALIVIZUMAB; VASCULOTROPIN;

EID: 77953673590     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.2.3.11779     Document Type: Review
Times cited : (115)

References (85)
  • 1
    • 0004257938 scopus 로고    scopus 로고
    • Lippencott Williams & Wilkins, New York
    • Paul WE. Fundamental Immunology, Lippencott Williams & Wilkins, New York 2003.
    • (2003) Fundamental Immunology
    • Paul, W.E.1
  • 3
    • 64949085560 scopus 로고    scopus 로고
    • Therapeutic antibodies: Current state and future trends-is a paradigm change coming soon?
    • Dimitrov DS, Marks JD. Therapeutic antibodies: Current state and future trends-is a paradigm change coming soon? Meth Mol Biol 2009; 525:1-27.
    • (2009) Meth Mol Biol , vol.525 , pp. 1-27
    • Dimitrov, D.S.1    Marks, J.D.2
  • 4
    • 0016756272 scopus 로고
    • Continuous cultures of fused cells secreting antibody of predefined specificity
    • Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-497
    • (1975) Nature , vol.256 , pp. 495-497
    • Kohler, G.1    Milstein, C.2
  • 5
    • 0021818675 scopus 로고
    • Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface
    • Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985; 228:1315-1317
    • (1985) Science , vol.228 , pp. 1315-1317
    • Smith, G.P.1
  • 6
    • 0024461313 scopus 로고
    • Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli
    • DOI 10.1038/341544a0
    • Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 1989; 341:544-546 (Pubitemid 19252529)
    • (1989) Nature , vol.341 , Issue.6242 , pp. 544-546
    • Ward, E.S.1    Gussow, D.2    Griffiths, A.D.3    Jones, P.T.4    Winter, G.5
  • 7
    • 0024833055 scopus 로고
    • Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda
    • Huse WD, Sastry L, Iverson SA, Kang AS, ting-Mees M, Burton DR, et al. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 1989; 246:1275-1281
    • (1989) Science , vol.246 , pp. 1275-1281
    • Huse, W.D.1    Sastry, L.2    Iverson, S.A.3    Kang, A.S.4    Ting-Mees, M.5    Burton, D.R.6
  • 12
    • 0037350545 scopus 로고    scopus 로고
    • Immunotherapy: Past, present and future
    • Waldmann TA. Immunotherapy: past, present and future. Nat Med 2003; 9:269-277
    • (2003) Nat Med , vol.9 , pp. 269-277
    • Waldmann, T.A.1
  • 13
    • 33646352962 scopus 로고    scopus 로고
    • Potent antibody therapeutics by design
    • Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6:343-357
    • (2006) Nat Rev Immunol , vol.6 , pp. 343-357
    • Carter, P.J.1
  • 14
    • 62349132009 scopus 로고    scopus 로고
    • Monoclonal antibodies for cancer immunotherapy
    • Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet 2009; 373:1033-1040
    • (2009) Lancet , vol.373 , pp. 1033-1040
    • Weiner, L.M.1    Dhodapkar, M.V.2    Ferrone, S.3
  • 15
    • 57049155399 scopus 로고    scopus 로고
    • Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
    • Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008; 7:1001-1012
    • (2008) Nat Rev Drug Discov , vol.7 , pp. 1001-1012
    • Ashkenazi, A.1
  • 16
    • 60849128549 scopus 로고    scopus 로고
    • Monoclonal antibodies as innovative therapeutics
    • Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 2008; 9:423-430
    • (2008) Curr Pharm Biotechnol , vol.9 , pp. 423-430
    • Reichert, J.M.1
  • 17
    • 0036719574 scopus 로고    scopus 로고
    • Antibodies, viruses and vaccines
    • Burton DR. Antibodies, viruses and vaccines. Nat Rev Immunol 2002; 2:706-713
    • (2002) Nat Rev Immunol , vol.2 , pp. 706-713
    • Burton, D.R.1
  • 18
    • 38049094546 scopus 로고    scopus 로고
    • Antibody-based HIV-1 vaccines: Recent developments and future directions
    • Montefiori D, Sattentau Q, Flores J, Esparza J, Mascola J. Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med 2007; 4:348.
    • (2007) PLoS Med , vol.4 , pp. 348
    • Montefiori, D.1    Sattentau, Q.2    Flores, J.3    Esparza, J.4    Mascola, J.5
  • 19
    • 33646421976 scopus 로고    scopus 로고
    • Prophylactic human papillomavirus vaccines
    • Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006; 116:1167-1173
    • (2006) J Clin Invest , vol.116 , pp. 1167-1173
    • Lowy, D.R.1    Schiller, J.T.2
  • 20
    • 43849094005 scopus 로고    scopus 로고
    • Cardiotoxicity profile of trastuzumab
    • Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf 2008; 31:459-467
    • (2008) Drug Saf , vol.31 , pp. 459-467
    • Ewer, S.M.1    Ewer, M.S.2
  • 22
  • 23
    • 60049093113 scopus 로고    scopus 로고
    • Preclinical efficacy and safety models for mAbs: The challenge of developing effective model systems
    • Dixit R, Coats S. Preclinical efficacy and safety models for mAbs: the challenge of developing effective model systems. IDrugs 2009; 12:103-108
    • (2009) IDrugs , vol.12 , pp. 103-108
    • Dixit, R.1    Coats, S.2
  • 24
    • 46149098675 scopus 로고    scopus 로고
    • Managing premedications and the risk for reactions to infusional monoclonal antibody therapy
    • Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 2008; 13:725-732
    • (2008) Oncologist , vol.13 , pp. 725-732
    • Chung, C.H.1
  • 26
    • 54849437047 scopus 로고    scopus 로고
    • Prediction of immunogenicity: In silico paradigms, ex vivo and in vivo correlates
    • De Groot AS, McMurry J, Moise L. Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr Opin Pharmacol 2008; 8:620-626
    • (2008) Curr Opin Pharmacol , vol.8 , pp. 620-626
    • De Groot, A.S.1    McMurry, J.2    Moise, L.3
  • 27
    • 62249171454 scopus 로고    scopus 로고
    • Strategies for preclinical immunogenicity assessment of protein therapeutics
    • Stas P, Lasters I. Strategies for preclinical immunogenicity assessment of protein therapeutics. IDrugs 2009; 12:169-173
    • (2009) IDrugs , vol.12 , pp. 169-173
    • Stas, P.1    Lasters, I.2
  • 29
    • 64249160740 scopus 로고    scopus 로고
    • Reducing the immunogenicity of protein therapeutics
    • Onda M. Reducing the immunogenicity of protein therapeutics. Curr Drug Targets 2009; 10:131-139
    • (2009) Curr Drug Targets , vol.10 , pp. 131-139
    • Onda, M.1
  • 30
    • 46149124807 scopus 로고    scopus 로고
    • How to predict and prevent the immunogenicity of therapeutic proteins
    • DOI 10.1016/S1387-2656(08)00007-0, PII S1387265608000070
    • Schellekens H. How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev 2008; 14:191-202. (Pubitemid 351903454)
    • (2008) Biotechnology Annual Review , vol.14 , pp. 191-202
    • Schellekens, H.1
  • 31
    • 0038476357 scopus 로고    scopus 로고
    • Immunogenicity of therapeutic monoclonal antibodies
    • Pendley C, Schantz A, Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 2003; 5:172-179
    • (2003) Curr Opin Mol Ther , vol.5 , pp. 172-179
    • Pendley, C.1    Schantz, A.2    Wagner, C.3
  • 33
    • 33344479421 scopus 로고    scopus 로고
    • Antiviral antibody responses: The two extremes of a wide spectrum
    • DOI 10.1038/nri1783
    • Hangartner L, Zinkernagel RM, Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 2006; 6:231-243 (Pubitemid 43290992)
    • (2006) Nature Reviews Immunology , vol.6 , Issue.3 , pp. 231-243
    • Hangartner, L.1    Zinkernagel, R.M.2    Hengartner, H.3
  • 34
    • 70349769842 scopus 로고    scopus 로고
    • Human immunoglobulin allotypes: Possible implications for immunogenicity
    • Jefferis R, Lefranc MP. Human immunoglobulin allotypes: Possible implications for immunogenicity. mAbs 2009; 1:332-338
    • (2009) MAbs , vol.1 , pp. 332-338
    • Jefferis, R.1    Lefranc, M.P.2
  • 36
    • 45149122101 scopus 로고    scopus 로고
    • Newer monoclonal antibodies for hematological malignancies
    • DOI 10.1016/j.exphem.2008.04.018, PII S0301472X08002075
    • Castillo J, Winer E, Quesenberry P. Newer monoclonal antibodies for hematological malignancies. Exp Hematol 2008; 36:755-768 (Pubitemid 351826873)
    • (2008) Experimental Hematology , vol.36 , Issue.7 , pp. 755-768
    • Castillo, J.1    Winer, E.2    Quesenberry, P.3
  • 37
    • 59549083317 scopus 로고    scopus 로고
    • Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
    • Mariani G, Fasolo A, De BE, Gianni L. Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol 2009; 6:93-104.
    • (2009) Nat Clin Pract Oncol , vol.6 , pp. 93-104
    • Mariani, G.1    Fasolo, A.2    De, B.E.3    Gianni, L.4
  • 38
    • 60849094827 scopus 로고    scopus 로고
    • Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer
    • Bedard PL, Piccart-Gebhart MJ. Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer. Clin Breast Cancer 2008; 8:157-165
    • (2008) Clin Breast Cancer , vol.8 , pp. 157-165
    • Bedard, P.L.1    Piccart-Gebhart, M.J.2
  • 39
    • 57649183358 scopus 로고    scopus 로고
    • Current perspective-trastuzumab
    • Hall PS, Cameron DA. Current perspective-trastuzumab. Eur J Cancer 2009; 45:12-18
    • (2009) Eur J Cancer , vol.45 , pp. 12-18
    • Hall, P.S.1    Cameron, D.A.2
  • 40
    • 56549113680 scopus 로고    scopus 로고
    • A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses
    • Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112:533-543
    • (2008) Breast Cancer Res Treat , vol.112 , pp. 533-543
    • Cameron, D.1    Casey, M.2    Press, M.3    Lindquist, D.4    Pienkowski, T.5    Romieu, C.G.6
  • 41
    • 55849130720 scopus 로고    scopus 로고
    • Novel anti-angiogenic therapies for malignant gliomas
    • Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 2008; 7:1152-1160
    • (2008) Lancet Neurol , vol.7 , pp. 1152-1160
    • Norden, A.D.1    Drappatz, J.2    Wen, P.Y.3
  • 42
    • 58149232648 scopus 로고    scopus 로고
    • Evolution of bevacizumabbased therapy in the management of breast cancer
    • Sachdev JC, Jahanzeb M. Evolution of bevacizumabbased therapy in the management of breast cancer. Clin Breast Cancer 2008; 8:402-410
    • (2008) Clin Breast Cancer , vol.8 , pp. 402-410
    • Sachdev, J.C.1    Jahanzeb, M.2
  • 43
    • 55549105059 scopus 로고    scopus 로고
    • Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer
    • Patel DK. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy 2008; 28:31-41.
    • (2008) Pharmacotherapy , vol.28 , pp. 31-41
    • Patel, D.K.1
  • 44
    • 65549152525 scopus 로고    scopus 로고
    • Monoclonal antibody therapies for solid tumors
    • Tassev DV, Cheung NK. Monoclonal antibody therapies for solid tumors. Expert Opin Biol Ther 2009; 9:341-353
    • (2009) Expert Opin Biol Ther , vol.9 , pp. 341-353
    • Tassev, D.V.1    Cheung, N.K.2
  • 45
    • 38449090309 scopus 로고    scopus 로고
    • Monoclonal antibody therapy for prostate cancer
    • Jakobovits A. Monoclonal antibody therapy for prostate cancer. Handb Exp Pharmacol 2008; 237-256
    • (2008) Handb Exp Pharmacol , pp. 237-256
    • Jakobovits, A.1
  • 47
    • 55949131238 scopus 로고    scopus 로고
    • Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent crossreactive HIV-1 neutralizers
    • Chen W, Zhu Z, Feng Y, Dimitrov DS. Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent crossreactive HIV-1 neutralizers. Proc Natl Acad Sci USA 2008; 105:17121-17126
    • (2008) Proc Natl Acad Sci USA , vol.105 , pp. 17121-17126
    • Chen, W.1    Zhu, Z.2    Feng, Y.3    Dimitrov, D.S.4
  • 48
    • 48549105161 scopus 로고    scopus 로고
    • Molecular engineering and design of therapeutic antibodies
    • Presta LG. Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 2008; 20:460-470
    • (2008) Curr Opin Immunol , vol.20 , pp. 460-470
    • Presta, L.G.1
  • 49
    • 61649087668 scopus 로고    scopus 로고
    • Glycosylation as a strategy to improve antibody-based therapeutics
    • Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009; 8:226-234
    • (2009) Nat Rev Drug Discov , vol.8 , pp. 226-234
    • Jefferis, R.1
  • 50
  • 51
    • 52949085848 scopus 로고    scopus 로고
    • Ertumaxomab: A trifunctional antibody for breast cancer treatment
    • Kiewe P, Thiel E. Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs 2008; 17:1553-1558
    • (2008) Expert Opin Investig Drugs , vol.17 , pp. 1553-1558
    • Kiewe, P.1    Thiel, E.2
  • 52
    • 61349114199 scopus 로고    scopus 로고
    • Ipilimumab: Controversies in its development, utility and autoimmune adverse events
    • Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009; 58:823-830
    • (2009) Cancer Immunol Immunother , vol.58 , pp. 823-830
    • Weber, J.1
  • 53
    • 58149483422 scopus 로고    scopus 로고
    • CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
    • Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci USA 2008; 105:20410-20415
    • (2008) Proc Natl Acad Sci USA , vol.105 , pp. 20410-20415
    • Yuan, J.1    Gnjatic, S.2    Li, H.3    Powel, S.4    Gallardo, H.F.5    Ritter, E.6
  • 54
    • 62449168519 scopus 로고    scopus 로고
    • TRAIL agonists on clinical trials for cancer therapy: The promises and the challenges
    • Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 2009; 4:34-41.
    • (2009) Rev Recent Clin Trials , vol.4 , pp. 34-41
    • Bellail, A.C.1    Qi, L.2    Mulligan, P.3    Chhabra, V.4    Hao, C.5
  • 57
    • 33846175669 scopus 로고    scopus 로고
    • Novel approaches for identification of broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies and improvement of their potency
    • Zhang MY, Dimitrov DS. Novel approaches for identification of broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies and improvement of their potency. Curr Pharm Des 2007; 13:203-212
    • (2007) Curr Pharm des , vol.13 , pp. 203-212
    • Zhang, M.Y.1    Dimitrov, D.S.2
  • 58
    • 67949120214 scopus 로고    scopus 로고
    • A large library based on a novel (CH2) scaffold: Identification of HIV-1 inhibitors
    • Xiao X, Feng Y, Vu BK, Ishima R, Dimitrov DS. A large library based on a novel (CH2) scaffold: identification of HIV-1 inhibitors. Biochem Biophys Res Commun 2009; 387:387-392
    • (2009) Biochem Biophys Res Commun , vol.387 , pp. 387-392
    • Xiao, X.1    Feng, Y.2    Vu, B.K.3    Ishima, R.4    Dimitrov, D.S.5
  • 61
    • 58749110914 scopus 로고    scopus 로고
    • Implementation of advanced technologies in commercial monoclonal antibody production
    • Zhou JX, Tressel T, Yang X, Seewoester T. Implementation of advanced technologies in commercial monoclonal antibody production. Biotechnol J 2008; 3:1185-1200
    • (2008) Biotechnol J , vol.3 , pp. 1185-1200
    • Zhou, J.X.1    Tressel, T.2    Yang, X.3    Seewoester, T.4
  • 64
    • 62049083943 scopus 로고    scopus 로고
    • Structural and functional bases for broadspectrum neutralization of avian and human influenza a viruses
    • Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, et al. Structural and functional bases for broadspectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009; 16:265-273
    • (2009) Nat Struct Mol Biol , vol.16 , pp. 265-273
    • Sui, J.1    Hwang, W.C.2    Perez, S.3    Wei, G.4    Aird, D.5    Chen, L.M.6
  • 67
    • 67651017498 scopus 로고    scopus 로고
    • Broad neutralizing human monoclonal antibodies against influenza virus from vaccinated healthy donors
    • Kubota-Koketsu R, Mizuta H, Oshita M, Ideno S, Yunoki M, Kuhara M, et al. Broad neutralizing human monoclonal antibodies against influenza virus from vaccinated healthy donors. Biochem Biophys Res Commun 2009; 387:180-185
    • (2009) Biochem Biophys Res Commun , vol.387 , pp. 180-185
    • Kubota-Koketsu, R.1    Mizuta, H.2    Oshita, M.3    Ideno, S.4    Yunoki, M.5    Kuhara, M.6
  • 69
    • 63449100805 scopus 로고    scopus 로고
    • Vaccines for lymphomas: Idiotype vaccines and beyond
    • Houot R, Levy R. Vaccines for lymphomas: idiotype vaccines and beyond. Blood Rev 2009; 23:137-142
    • (2009) Blood Rev , vol.23 , pp. 137-142
    • Houot, R.1    Levy, R.2
  • 70
    • 57749203373 scopus 로고    scopus 로고
    • Therapeutic potential of vaccines in the management of hypertension
    • Brown MJ. Therapeutic potential of vaccines in the management of hypertension. Drugs 2008; 68:2557-2560
    • (2008) Drugs , vol.68 , pp. 2557-2560
    • Brown, M.J.1
  • 72
    • 58149307496 scopus 로고    scopus 로고
    • Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy
    • Baxevanis CN, Perez SA, Papamichail M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother 2009; 58:317-324
    • (2009) Cancer Immunol Immunother , vol.58 , pp. 317-324
    • Baxevanis, C.N.1    Perez, S.A.2    Papamichail, M.3
  • 73
    • 55549114992 scopus 로고    scopus 로고
    • Structure-based antigen design: A strategy for next generation vaccines
    • Dormitzer PR, Ulmer JB, Rappuoli R. Structure-based antigen design: a strategy for next generation vaccines. Trends Biotechnol 2008; 26:659-667
    • (2008) Trends Biotechnol , vol.26 , pp. 659-667
    • Dormitzer, P.R.1    Ulmer, J.B.2    Rappuoli, R.3
  • 75
    • 63149104746 scopus 로고    scopus 로고
    • Mechanistic studies of the immunochemical termination of self-tolerance with unnatural amino acids
    • Grunewald J, Hunt GS, Dong L, Niessen F, Wen BG, Tsao ML, et al. Mechanistic studies of the immunochemical termination of self-tolerance with unnatural amino acids. Proc Natl Acad Sci USA 2009; 106:4337-4342
    • (2009) Proc Natl Acad Sci USA , vol.106 , pp. 4337-4342
    • Grunewald, J.1    Hunt, G.S.2    Dong, L.3    Niessen, F.4    Wen, B.G.5    Tsao, M.L.6
  • 76
    • 70449701456 scopus 로고    scopus 로고
    • Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens
    • Xiao X, Chen W, Feng Y, Zhu Z, Prabakaran P, Wang Y, et al. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun 2009; 390:404-409
    • (2009) Biochem Biophys Res Commun , vol.390 , pp. 404-409
    • Xiao, X.1    Chen, W.2    Feng, Y.3    Zhu, Z.4    Prabakaran, P.5    Wang, Y.6
  • 79
    • 65949114941 scopus 로고    scopus 로고
    • All known cross reactive HIV-1 neutralizing antibodies are highly divergent from germline and their elicitation may require prolonged periods of time
    • Chen W, Zhu Z, Zhang M, Macagno A, Prabakaran P, Owens J, et al. All known cross reactive HIV-1 neutralizing antibodies are highly divergent from germline and their elicitation may require prolonged periods of time. AIDS Res Hum Retroviruses 2008; 24:11-12
    • (2008) AIDS Res Hum Retroviruses , vol.24 , pp. 11-12
    • Chen, W.1    Zhu, Z.2    Zhang, M.3    Macagno, A.4    Prabakaran, P.5    Owens, J.6
  • 80
    • 77953655567 scopus 로고    scopus 로고
    • Maturation pathways of cross-reactive HIV-1 neutralizing antibodies
    • Xiao X, Chen W, Feng Y, Dimitrov DS. Maturation pathways of cross-reactive HIV-1 neutralizing antibodies. Viruses 2009; 1:802-817
    • (2009) Viruses , vol.1 , pp. 802-817
    • Xiao, X.1    Chen, W.2    Feng, Y.3    Dimitrov, D.S.4
  • 81
    • 0033367383 scopus 로고    scopus 로고
    • The immunome
    • Pederson T. The immunome. Mol Immunol 1999; 36:1127-1128
    • (1999) Mol Immunol , vol.36 , pp. 1127-1128
    • Pederson, T.1
  • 82
    • 63849131879 scopus 로고    scopus 로고
    • Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
    • Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009; 458:636-640
    • (2009) Nature , vol.458 , pp. 636-640
    • Scheid, J.F.1    Mouquet, H.2    Feldhahn, N.3    Seaman, M.S.4    Velinzon, K.5    Pietzsch, J.6
  • 83
    • 0041689676 scopus 로고    scopus 로고
    • Predominant autoantibody production by early human B cell precursors
    • DOI 10.1126/science.1086907
    • Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science 2003; 301:1374-1377 (Pubitemid 37075812)
    • (2003) Science , vol.301 , Issue.5638 , pp. 1374-1377
    • Wardemann, H.1    Yurasov, S.2    Schaefer, A.3    Young, J.W.4    Meffre, E.5    Nussenzweig, M.C.6
  • 85
    • 73949116413 scopus 로고    scopus 로고
    • Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire
    • Glanville J, Zhai W, Berka J, Telman D, Huerta G, Mehta GR, et al. Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire. Proc Natl Acad Sci USA 2009; 106:20216-20221
    • (2009) Proc Natl Acad Sci USA , vol.106 , pp. 20216-20221
    • Glanville, J.1    Zhai, W.2    Berka, J.3    Telman, D.4    Huerta, G.5    Mehta, G.R.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.